These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 7848546)
1. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Sears MR; Taylor DR Drug Saf; 1994 Oct; 11(4):259-83. PubMed ID: 7848546 [TBL] [Abstract][Full Text] [Related]
7. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? Beasley R; Pearce N; Crane J; Burgess C J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S18-30. PubMed ID: 10452785 [TBL] [Abstract][Full Text] [Related]
8. Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV; Boushey HA Clin Chest Med; 1995 Dec; 16(4):715-33. PubMed ID: 8565410 [TBL] [Abstract][Full Text] [Related]
9. Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis. Hancox RJ Clin Rev Allergy Immunol; 2006; 31(2-3):279-88. PubMed ID: 17085800 [TBL] [Abstract][Full Text] [Related]
10. [The effect of adrenergic beta agonists on morbidity and mortality of asthma]. Bousquet J; Godard P; Michel FB Presse Med; 1993 Feb; 22(7):308-13. PubMed ID: 8099222 [TBL] [Abstract][Full Text] [Related]
11. The use of beta-agonists and the risk of death and near death from asthma. Spitzer WO; Suissa S; Ernst P; Horwitz RI; Habbick B; Cockcroft D; Boivin JF; McNutt M; Buist AS; Rebuck AS N Engl J Med; 1992 Feb; 326(8):501-6. PubMed ID: 1346340 [TBL] [Abstract][Full Text] [Related]
13. Confounding by indication and channeling over time: the risks of beta 2-agonists. Blais L; Ernst P; Suissa S Am J Epidemiol; 1996 Dec; 144(12):1161-9. PubMed ID: 8956629 [TBL] [Abstract][Full Text] [Related]
14. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Garrett JE; Lanes SF; Kolbe J; Rea HH Thorax; 1996 Nov; 51(11):1093-9. PubMed ID: 8958891 [TBL] [Abstract][Full Text] [Related]
15. End of the New Zealand asthma mortality epidemic. Pearce N; Beasley R; Crane J; Burgess C; Jackson R Lancet; 1995 Jan; 345(8941):41-4. PubMed ID: 7799709 [TBL] [Abstract][Full Text] [Related]
16. Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids. Hancox RJ; Taylor DR BioDrugs; 2001; 15(1):11-24. PubMed ID: 11437672 [TBL] [Abstract][Full Text] [Related]
17. Safety of long-acting beta2-agonists in the treatment of asthma. Cazzola M; Matera MG Ther Adv Respir Dis; 2007 Oct; 1(1):35-46. PubMed ID: 19124346 [TBL] [Abstract][Full Text] [Related]
18. Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic. Beasley R; Pearce N; Crane J; Burgess C Int Arch Allergy Immunol; 1995; 107(1-3):325-7. PubMed ID: 7613161 [TBL] [Abstract][Full Text] [Related]
19. Re: "Confounding by indication and channeling over time: the risks of beta2-agonists". Pearce N; Beasley R; Crane J; Burgess C Am J Epidemiol; 1997 Nov; 146(10):885-7. PubMed ID: 9384211 [No Abstract] [Full Text] [Related]
20. Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic. Suissa S; Ernst P J Clin Epidemiol; 1997 Oct; 50(10):1079-88. PubMed ID: 9368515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]